10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

CDC42EP3 Rabbit pAb

Catalog # AP99597

Product Information

Application	IHC-P, IHC-F, IF
Primary Accession	Q9UKI2
Other Accession	Q9UKI2
Reactivity	Mouse
Predicted	Rat, Pig, Human, Chicken, Dog, Horse, Sheep
Host	Rabbit
Clonality	Polyclonal
Calculated MW	27678
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human CDC42EP3
Epitope Specificity	11-110/254
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SIMILARITY	Belongs to the BORG/CEP family.Contains 1 CRIB domain.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	CDC42EP3 is probably involved in the organization of the actin cytoskeleton. May act downstream of CDC42 to induce actin filament assembly leading to cell shape changes. It induces pseudopodia formation in fibroblasts.

Additional Information

Gene ID	10602
Other Names	BORG2; CEP3; UB1; BORG2_HUMAN; CDC42EP3; Binder of Rho GTPases 2; MSE55-related Cdc42-binding protein; CDC42 effector protein 3; CDC42 effector protein (Rho GTPase binding) 3
Dilution	IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Protein Information

Name	CDC42EP3
Synonyms	BORG2, CEP3

Function	Probably involved in the organization of the actin cytoskeleton. May act downstream of CDC42 to induce actin filament assembly leading to cell shape changes. Induces pseudopodia formation in fibroblasts.
Cellular Location	Endomembrane system; Peripheral membrane protein. Cytoplasm, cytoskeleton
Tissue Location	Highly expressed in the heart and weakly in the brain.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.